在渐进的多发性硬化症中使用免疫疗法
Tradite Neziraj1, Ludwig Kappos2, Anne-Katrin Pröbstel3
1Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Departments of Biomedicine and of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.
Handbook of clinical neurology
|January 12, 2026
概括
多发性硬化症 (MS) 是一种自身免疫性中枢神经系统疾病. 进展,而不仅仅是复发,驱动残疾,需要专注于潜在的神经退行过程的有效治疗.
科学领域:
- 神经免疫学 神经免疫学
- 神经退行发生神经退行.
- 中枢神经系统疾病 中枢神经系统疾病
背景情况:
- 多发性硬化症 (MS) 是一种自身免疫性中枢神经系统疾病,具有遗传和环境风险因素.
- 虽然已知复发和进展过程,但疾病进展现在被认为是MS患者神经障碍的主要驱动因素.
- 了解MS进展的病理生理学对于开发向疗法至关重要.
研究的目的:
- 突出疾病进展在多发性硬化症中累积神经障碍中的关键作用.
- 强调需要定义驱动多发性硬化症进展的主导病理生理过程.
- 讨论提升知识对开发向免疫调节疗法的影响.
主要方法:
- 审查目前对MS病理生理学的理解,重点关注渐进的方面.
- 分析病理特征,包括中枢神经系统炎症和神经退行.
- 检查不断发展的临床试验设计和对MS进展的评估措施.
主要成果:
- 渐进性因素是所有多发性硬化症临床课程中神经障碍累积的主要因素.
- 病理学特征包括分隔的中枢神经系统炎症和神经退行性过程,导致神经轴和突触损失.
- 对病理生理学的日益增长的理解支持针对渐进性MS的向免疫调节治疗的开发.
结论:
- 定义驱动多发性硬化症进展的主导病理生理过程是必不可少的.
- 新的临床试验设计和先进的评估措施为个性化治疗方案提供了机会.
- 针对性免疫调节疗法正在出现,基于改善的病理生理学理解,治疗渐进性多发性硬化.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines
946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K


